Xeris Biopharma Holdings, Inc. (0A8E.L)

USD 3.29

(-4.76%)

Total Debt Summary of Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.'s latest annual total debt in 2024 was 229.19 Million USD , up 15.72% from previous year.
Xeris Biopharma Holdings, Inc.'s latest quarterly total debt in 2024 FY was 229.19 Million USD , up 15.72% from previous quarter.
Xeris Biopharma Holdings, Inc. reported annual total debt of 198.05 Million USD in 2023, down 0.0% from previous year.
Xeris Biopharma Holdings, Inc. reported annual total debt of 198.05 Million USD in 2022, up 124.89% from previous year.
Xeris Biopharma Holdings, Inc. reported quarterly total debt of 229.19 Million USD for 2024 Q2, up 0.55% from previous quarter.
Xeris Biopharma Holdings, Inc. reported quarterly total debt of 229.19 Million USD for 2024 FY, up 15.72% from previous quarter.

Annual Total Debt Chart of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Historical Annual Total Debt of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Year	Total Debt	Total Debt Growth
2024	229.19 Million USD	15.72%
2023	198.05 Million USD	0.0%
2022	198.05 Million USD	124.89%
2021	88.06 Million USD	1.2%
2020	87.02 Million USD	172.88%
2019	31.89 Million USD	0.0%
2018	- USD	0.0%
2017	- USD	0.0%

Year	Total Debt	Total Debt Growth
2024 Q3	268.69 Million USD	17.24%
2024 Q2	229.19 Million USD	0.55%
2024 FY	229.19 Million USD	15.72%
2024 Q1	227.94 Million USD	1.31%
2024 Q4	269.8 Million USD	0.41%
2023 Q3	198.41 Million USD	-11.81%
2023 Q4	224.98 Million USD	13.39%
2023 FY	198.05 Million USD	0.0%
2023 Q1	138.5 Million USD	0.32%
2023 Q2	224.98 Million USD	62.44%
2022 Q4	138.06 Million USD	0.06%
2022 FY	198.05 Million USD	124.89%
2022 Q3	137.98 Million USD	56.68%
2022 Q2	88.06 Million USD	0.4%
2022 Q1	87.71 Million USD	0.27%
2021 Q4	87.47 Million USD	0.24%
2021 Q1	119.39 Million USD	9.06%
2021 Q2	87.02 Million USD	-27.11%
2021 Q3	87.27 Million USD	0.29%
2021 FY	88.06 Million USD	1.2%
2020 FY	87.02 Million USD	172.88%
2020 Q3	58.48 Million USD	0.31%
2020 Q2	58.3 Million USD	0.31%
2020 Q1	58.12 Million USD	79.38%
2020 Q4	109.47 Million USD	87.19%
2019 Q1	31.64 Million USD	74.17%
2019 FY	31.89 Million USD	0.0%
2019 Q4	32.4 Million USD	0.82%
2019 Q3	32.14 Million USD	0.79%
2019 Q2	31.89 Million USD	0.78%
2018 Q2	- USD	0.0%
2018 Q4	18.16 Million USD	0.64%
2018 FY	- USD	0.0%
2018 Q3	18.05 Million USD	0.0%
2017 Q3	- USD	0.0%
2017 FY	- USD	0.0%

Peer Total Debt Comparison of Xeris Biopharma Holdings, Inc.

Name	Total Debt	Total Debt Difference
Arrowhead Pharmaceuticals, Inc.	115.17 Million USD	-99.001%
Codexis, Inc.	22.36 Million USD	-924.821%
Viridian Therapeutics, Inc.	21.04 Million USD	-988.897%
Organovo Holdings, Inc.	1.39 Million USD	-16341.248%